
ABPO
Healthcare · Biotechnology · $3.1M market cap
$0.4650-0.04 (-8.8%)Nov 13, 10:26 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 2, 2026 | Time not confirmed | — | -0.16 | — |
| Jun 3, 2026 | Time not confirmed | — | -0.23 | — |
| Feb 25, 2026 | Time not confirmed | — | 2.06 | — |
| Nov 14, 2025 | After the close | -1.20 | -0.63 | +47.5% |
| Aug 13, 2025 | After the close | -1.20 | -1.50 | -25.0% |
| May 15, 2025 | After the close | -1.20 | -2.40 | -100.0% |
| Feb 26, 2025 | Time not confirmed | -1.20 | -9.60 | -700.0% |
| Nov 27, 2024 | Time not confirmed | — | -1.23 | — |
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an…